Metastasis is a major cause of morbidity and mortality in cancer patients. However, the
molecular and cellular mechanisms underlying the ability of cancer cells to metastasize …

Over the past several years, we have witnessed a resurgence of interest in the biology and
therapeutic vulnerabilities of small-cell lung cancer (SCLC). This has been driven in part …

Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with a unique
natural history characterized by a short doubling time, high growth fraction, and early …

Small cell lung cancer (SCLC) is an aggressive malignancy with a distinct natural history
and dismal prognosis. Given its predisposition for early dissemination, patients are …

Small cell lung cancer (SCLC) is a particular subtype of lung cancer with high mortality.
Recent advances in understanding SCLC genomics and breakthroughs of immunotherapy …

Lung cancer is the leading cause of cancer deaths, with small cell lung cancer (SCLC)
representing the most aggressive subtype. Standard treatments have not changed in …

Small cell lung cancer (SCLC) is one of the four major histological types of lung cancer. The
incidence of SCLC in developed countries has declined in recent years, presumably …

Although the incidence of small cell lung cancer (SCLC) has declined during the past 30
years, it remains a frustrating disease to research and treat. Numerous attempts to enhance …

Small cell lung cancer (SCLC) is an aggressive disease that accounts for approximately
14% of all lung cancers. In the United States, approximately 31,000 patients are diagnosed …

Small cell lung cancer (SCLC), originating from lung neuroendocrine stem cells, is a
common pulmonary malignant tumor. SCLC, with poor prognoses, accounts for …